Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc.
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(2451)
•••
Post by Eoganachton Dec 12, 2023 12:43pm
302 Views
Post# 35780196

New Paper from the McFarland Group

New Paper from the McFarland GroupRu(II) Phenanthroline-Based Oligothienyl Complexes as Phototherapy Agents

Houston D. Cole, Abbas Vali, John A. Roque III, Ge Shi, Gurleen Kaur, Rachel O. Hodges, Antonio Francs-Monerris, Marta E. Alberto*, Colin G. Cameron*, and Sherri A. McFarland*
 
Publication Date:December 11, 2023
 
 
For those with a chemistry degree and $48 to spare there is a new paper from Dr. McFarland and colleagues. They are continuing to investigate the phototherapeutic efficacy against melanoma cells of the Ruthenium based photosensitizers Ru-0T to Ru-4T.
 
Ru-3T and Ru-4T turn out to be the most phototoxic, and the most active when exposed to longer wavelengths (greater depth of penetration) and under hypoxic (low oxygen) conditions. The fully available paper from May 2022 about Ru-3T and Ru-4T describes how powerful they are in anti-cancer activity. It's scandalous how such important intellectual property is lying idle. One day these super PDCs may make a contribution against melanoma and other cancers if Theralase can ever get adequately funded.
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities